LncRNA GAS6 antisense RNA 1 facilitates the tumorigenesis of clear cell renal cell carcinoma by regulating the AMP‑activated protein kinase/mTOR signaling pathway
- Xiaoyun Guo
- Hongjun Li
- Mei Zhang
- Rong Li
Affiliations: Department of Nephrology, The Second Hospital of Tianjin Medical University, Hexi, Tianjin 300201, P.R. China, Department of Infectious Diseases and Immunology, The Second Hospital of Tianjin Medical University, Hexi, Tianjin 300201, P.R. China, Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Hexi, Tianjin 300201, P.R. China
- Published online on: August 10, 2021 https://doi.org/10.3892/ol.2021.12988
Copyright: © Guo
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The role of GAS6 antisense RNA 1 (GAS6‑AS1) in clear cell renal cell carcinoma (ccRCC) remains unclear. The aim of the present study was to investigate the role and molecular mechanisms of GAS6‑AS1 in the progression of ccRCC. GAS6‑AS1 was found to be upregulated in ccRCC tissues and cell lines, and patients with high GAS6‑AS1 expression levels exhibited a poor prognosis. Small interfering (si)RNA GAS6‑AS1 inhibited the activity, colony formation, invasiveness and glycolysis of OSRC‑2 and SW839 cells, while GAS6‑AS1 overexpression promoted these functions. Moreover, si‑GAS6‑AS1 increased the phosphorylation level of AMP‑activated protein kinase (AMPK) and decreased that of mTOR, as well as decreasing proliferating cell nuclear antigen (PCNA), MMP‑2 and hexokinase‑2 (HK2) expression, which were reversed by inhibiting AMPK or mTOR. In addition, the silencing of GAS6‑AS1 suppressed the growth of xenografted tumors and attenuated the expression of PCNA, MMP‑2 and HK2 in tumor tissues. These findings conclude that GAS6‑AS1 regulated the proliferation, invasiveness and glycolysis of ccRCC cells by regulating the AMPK/mTOR signaling pathway, and suggest that GAS6‑AS1 may be a potential therapeutic target for ccRCC.